Literature DB >> 9128331

A new probable increasing cause of esophageal ulceration: alendronate.

R E Colina1, M Smith, J W Kikendall, R K Wong.   

Abstract

We present a case of esophageal ulcerations caused by alendronate (Fosamax), a recently marketed medication. The patient presented with a chief complaint of retrosternal pain and severe odynophagia of 5 days duration. She was taking prednisone 10 mg and azathioprine 100 mg p.o. q.d. for systemic lupus erythematosus. To prevent osteoporosis, she was started on alendronate 10 mg q.d. 2 wk before her symptoms started. Endoscopy of the upper GI tract revealed two deep, large ulcers at the gastroesophageal junction. Multiple biopsy specimens revealed necroinflammatory debris and acute esophagitis. However, no organisms were identified, and the result of her HIV test (ELISA) was negative. Alendronate was discontinued, and her symptoms resolved completely in 1 wk. Follow-up endoscopy performed 4 wk later revealed complete healing of the ulcers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9128331

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

Review 1.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.

Authors:  D Jaspersen
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

3.  Dysphagia in the elderly.

Authors:  Muhammad Aslam; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-12

Review 4.  What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

5.  The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.

Authors:  Soichiro Itoh; Yohichi Sekino; Ken-ichi Shinomiya; Shu Takeda
Journal:  J Bone Miner Metab       Date:  2012-11-10       Impact factor: 2.626

6.  Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).

Authors:  Ellen Wright; Peter T Schofield; Paul Seed; Mariam Molokhia
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.